At the 44th Annual J.P. Morgan Healthcare Conference, CEO Nikhil Lalwani highlighted ANI Pharmaceuticals’ status as a profitable, high-growth biopharmaceutical company undergoing a transformation into a leading rare disease specialist. Management projects 2026 revenues exceeding $1.0 billion, a 26% increase year-on-year following 39% growth in 2025. The rare disease segment is expected to represent approximately 60% of total revenues, driven primarily by the launch and commercialization of purified Cortrophin Gel. ANI’s generics division continues to generate strong cash flow through robust R&D capabilities, U.S. manufacturing scale and operational execution, creating a feedback loop that funds further investment in rare disease assets.

In late 2025, ANI reported record annual results, with total revenue up by nearly 39% versus the prior year. For 2026, the company issued guidance of $1.055–$1.115 billion in revenues, reflecting a 60% year-over-year increase at the midpoint. Purified Cortrophin Gel is expected to contribute $540–$575 million in 2026 sales, supported by the addition of 90 commercial personnel, expanded patient outreach programs and the initiation of a pivotal Phase 4 trial designed to secure long-term label expansion and reimbursement across multiple rare disease indications.

ANI’s lead rare disease product, purified Cortrophin Gel, is forecast to deliver substantial durable growth over multiple years. With more than 80 active clinical sites and over 1,200 patients enrolled in ongoing studies, the product’s full U.S. launch is underpinned by comprehensive market access agreements and a targeted medical affairs strategy. Management expects gross margins on Cortrophin Gel to exceed 75% by year end, driven by manufacturing efficiencies at ANI’s Kalamazoo, Michigan facility and premium pricing for orphan drug status.

ANI trades at an 11.2x forward P/E ratio, representing a 43% discount to the broader specialty pharmaceutical sector average. As of December 31, 2025, the company held $285 million in cash and equivalents, with zero net debt and no anticipated cash burn in 2026. In recent sessions, ANI shares experienced a 10.6% intraday increase on above-average volume, though analysts caution that upward revisions in earnings estimates may already be largely priced in, limiting near-term upside potential.